MRMD Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.06 and $0.23. With a market capitalization of about $27.92 million, MariMed Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.34). Key stats such as the average daily volume over the past year has been around 646.09 thousand shares, volume is running light vs its 52-week average. Headquartered in Norwood, MA, MariMed Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Jon R. Levine, the company employs approximately 715 people and listed since August 03, 2012. MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally.

Average 10-day trading volume of 705.50 thousand shares is in line with the 3-month average of 653.76 thousand, indicating normal recent market interest.

MariMed Inc. trades at a P/E ratio of -2.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.18 and a price-to-book ratio of 0.61 suggesting the stock is closer to book value. The P/FCF stands at 5.06, also above market averages.

MariMed Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.11. This means the shares are trading below this model’s fair value.

MariMed Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by -20.4%. The prior quarter beat by -200.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 05, 2025.

Our AI price prediction model suggests that MariMed Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows MariMed Inc. trading at a premium to the broader market with a P/E of -2.33.